目前,恶性心包积液尚缺乏有效的长期控制手段,血管内皮生长因子(vascular endothelial growth factor,VEGF)在浆膜腔积液形成过程中起到了关键作用,而贝伐珠单抗作为VEGF的特异性抗体,可有效对抗积液产生。但是,贝伐珠单抗心包腔内给药尚未在临床上广泛应用,本文特报道1例肺癌合并心包积液患者应用贝伐珠单抗心包腔内灌注的病例,以供同行参考。 At present, malignant pericardial effusion is still lack of effective long-term control means, vascular endothelial growth factor (VEGF) plays a key role in the formation of serosal effusion, and bevacizumab as VEGF specific Sexual antibodies, can effectively fight the fluid production. However, the pericardial administration of bevacizumab has not been widely used in clinical practice. This article reports a case of pericardial perfusion of bevacizumab in patients with lung cancer complicated with pericardial effusion for peer reference.